Drugs' Net Price Only Growing Modestly, Express Scripts Finds
Overall unit cost in commercial insurance market was up only 2.5% in 2016 despite 11% list increase for brands, PBM's Drug Trend Report concludes; findings could be counterpoint to public and policymaker concerns with drug pricing.
You may also be interested in...
Price increases generated 100% of net US earnings growth at major biopharma firms in 2016, according to investment analyst report assessing threat of continued pricing pressure.
List pricing for Biogen’s Tecfidera and Novartis’ Gilenya would need to be discounted 47% and 50%, respectively, for them to be considered good values, ICER concludes in a new report. But three products come in under ICER's thresholds.
Indication-based drug pricing is one mechanism for pegging price to value. It will be tough to implement in the US without systemic change, but PBMs have plenty of incentives to make it work.